Skip to main content
SpringerLink
Log in

Cancer therapy

YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors

  • News & Views
  • Published:

From Nature Cancer

View current issue Submit your manuscript

The discovery and approval of direct KRAS inhibitors for clinical use showed that mutant KRAS is not, as previously thought, an ‘undruggable’ oncoprotein. But therapeutic success is limited by the rapid onset of resistance. Two studies now show that YAP and TAZ represent an actionable target for tackling adaptive resistance to KRAS inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Targeting adaptive resistance to KRAS inhibitors.

References

  1. Prior, I. A., Hood, F. E. & Hartley, J. L. Cancer Res. 80, 2969–2974 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Punekar, S., Velcheti, V., Neel, B. & Wong, K.-K. Nat. Rev. Clin. Oncol. 19, 637–655 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Awad, M. M. et al. N. Engl. J. Med. 384, 2382–2393 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Negrao, M. et al. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-22-1420 (2023).

    Article  PubMed  Google Scholar 

  5. Zhao, Y. et al. Nature 599, 679–683 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Xue, J. Y. et al. Nature 577, 421–425 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ryan, M. B. et al. Clin. Cancer Res. 26, 1633–1643 (2020).

    Article  CAS  PubMed  Google Scholar 

  8. Adachi, Y. et al. Clin. Cancer Res. 26, 5962–5973 (2020).

    Article  CAS  PubMed  Google Scholar 

  9. Adachi, Y. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00575-2 (2023).

    Article  PubMed  Google Scholar 

  10. Young, L. C. et al. Mol. Cell. 52, 679–692 (2013).

    Article  CAS  PubMed  Google Scholar 

  11. Kwon, J. J. et al. Nature 609, 408–415 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Solanki, H. S. et al. Clin. Cancer Res. 27, 2533–2548 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hagenbeek, T. Nat. Cancer https://doi.org/10.1038/s43018-023-00577-0 (2023).

    Article  PubMed  Google Scholar 

  14. Piccolo, S., Panciera, T., Contessotto, P. & Cordenonsi, M. Nat. Cancer 4, 9–26 (2023).

    CAS  PubMed  Google Scholar 

  15. Dey, A., Varelas, X. & Guan, K. Nat. Rev. Drug Discov. 19, 480–494 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy

    Alessia Mira & Chiara Ambrogio

Authors
  1. Alessia Mira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Ambrogio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chiara Ambrogio.

Ethics declarations

Competing interests

C.A. has received research fees from Revolution Medicines, Aelin Therapeutics, Verastem, Roche and Boehringer-Ingelheim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mira, A., Ambrogio, C. YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors. Nat Cancer 4, 784–786 (2023). https://doi.org/10.1038/s43018-023-00580-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00580-5

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation